ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

April issue of Business & Regulatory Report included (8 additional pages).

April 30, 2004

Funding opportunities listed.

January 2, 2004

Group Chairmen Approve Policy On Industry Support; NCI Turns Down Request To “Launder” Contributions

December 16, 1983

In Surgery vs Radiotherapy, Outcome Differences Equalize After 15 Years Follow-up

February 22, 2013

A.D. Little Gets 42.4 Million Contract Award

May 2, 1975

Prevention Task Force Unable To Reach Consensus On New Division, Tries To Avoid More Disruption

July 6, 1979